Stephens Inc. AR decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 174,732 shares of the biopharmaceutical company’s stock after selling 2,878 shares during the quarter. Stephens Inc. AR’s holdings in Bristol-Myers Squibb were worth $11,137,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Regal Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the third quarter worth $252,000. Waldron LP bought a new stake in shares of Bristol-Myers Squibb during the third quarter worth $243,000. Hikari Power Ltd raised its position in shares of Bristol-Myers Squibb by 23.4% during the third quarter. Hikari Power Ltd now owns 84,800 shares of the biopharmaceutical company’s stock worth $5,405,000 after acquiring an additional 16,100 shares during the last quarter. Vaughan David Investments Inc. IL raised its position in shares of Bristol-Myers Squibb by 3,163.9% during the third quarter. Vaughan David Investments Inc. IL now owns 431,323 shares of the biopharmaceutical company’s stock worth $13,742,000 after acquiring an additional 418,108 shares during the last quarter. Finally, Banque Pictet & Cie SA raised its position in shares of Bristol-Myers Squibb by 92.2% during the third quarter. Banque Pictet & Cie SA now owns 20,850 shares of the biopharmaceutical company’s stock worth $1,329,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 69.74% of the company’s stock.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.28 on Friday. The company has a market capitalization of $101,930.00, a PE ratio of 24.52, a P/E/G ratio of 2.14 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.77 EPS. equities analysts expect that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.
A number of equities research analysts have recently weighed in on BMY shares. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 target price for the company in a research report on Wednesday, September 27th. Jefferies Group restated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. UBS Group restated a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Finally, Barclays boosted their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $65.11.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://ledgergazette.com/2018/01/20/bristol-myers-squibb-co-bmy-shares-sold-by-stephens-inc-ar.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.